XML 108 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaboration with Janssen Biotech, Inc. (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
Accounts receivable, net $ 5,428 $ 5,384  
Accounts payable and accrued liabilities $ 11,832 11,931  
Collaborative arrangement      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
Share of collaboration development costs responsible by the entity 40.00%    
Global - AbbVie's share of other costs (included in respective line items) $ 321 326 $ 288
Collaborative arrangement | International      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
International - AbbVie's share of profits (included in net revenues) 844 622 429
Collaborative arrangement | Janssen Biotech, Inc      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
Milestone payments $ 200    
Share of collaboration development costs responsible by Janssen 60.00%    
Accounts receivable, net $ 235 177  
Accounts payable and accrued liabilities 455 376  
Collaborative arrangement | Janssen Biotech, Inc | United States      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
United States - Janssen's share of profits (included in cost of products sold) $ 1,803 $ 1,372 $ 1,001